{"filing":{"accession_number":"0001171843-26-005860","cik":"0001756594","ticker":"IVEVF","company_name":"Inventiva S.A.","form":"6-K","filing_date":"2026-09-03","report_date":"2026-09-02","primary_document":"f6k_090226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1756594/000117184326005860/f6k_090226.htm"},"events":[{"id":31427,"run_id":28833,"accession_number":"0001171843-26-005860","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of the last patient visit in the NATiV3 Phase 3 clinical trial of lanifibranor for MASH treatment, with topline results expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biopharmaceutical company whose lead product candidate is in pivotal Phase 3 testing. The event is operational/strategic (a key trial milestone) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings release, M\u0026A, or other named types. The company has received FDA Breakthrough Therapy and Fast Track designations, and successful trial results could support regulatory submission and commercialization in 2027–2028, making this milestone material to investors assessing the company's pipeline progress and value.","company_name":"Inventiva S.A.","ticker":"IVEVF","filing_date":"2026-09-03","form":"6-K","submitted_at":null,"items":[{"id":34300,"accession_number":"0001171843-26-005860","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of the last patient visit in the NATiV3 Phase 3 clinical trial of lanifibranor for MASH treatment, with topline results expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biopharmaceutical company whose lead product candidate is in pivotal Phase 3 testing. The event is operational/strategic (a key trial milestone) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings release, M\u0026A, or other named types. The company has received FDA Breakthrough Therapy and Fast Track designations, and successful trial results could support regulatory submission and commercialization in 2027–2028, making this milestone material to investors assessing the company's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:05:22.516265+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34300,"accession_number":"0001171843-26-005860","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of the last patient visit in the NATiV3 Phase 3 clinical trial of lanifibranor for MASH treatment, with topline results expected in Q4 2026. This is a material clinical development milestone for a clinical-stage biopharmaceutical company whose lead product candidate is in pivotal Phase 3 testing. The event is operational/strategic (a key trial milestone) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings release, M\u0026A, or other named types. The company has received FDA Breakthrough Therapy and Fast Track designations, and successful trial results could support regulatory submission and commercialization in 2027–2028, making this milestone material to investors assessing the company's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:05:22.516265+00:00","company_name":"Inventiva S.A.","ticker":"IVEVF","filing_date":"2026-09-03"}]}